Lifileucel is T cell immunotherapy or tumor-infiltrating lymphocyte (TIL) therapy. The cells are derived from the effective T-cell population within the patient’s tumor. After effective lymphocytes are removed, they are grown and multiplied in a lab, and then reintroduced back into the patient’s body.
The therapy is approved under accelerated approval for the treatment of patients with advanced melanoma.
Click here to learn more about this therapy.